Amgen Research (munich) Gmbh

Amgen Research Gmbh

Ines Herrmann

Peter Kufer

Tobias Raum

Patrick Hoffmann

Doris Rau

Markus Muenz

Ralf Lutterbüse

Andreas Wolf

Benno Rattel

Elisabeth Nahrwold

Cornelius Pompe

Ralf Lutterbuese

Johannes Brozy

Markus Münz

Matthias Friedrich

Pamela Bogner

Markus Munz

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3

The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, wherein serum albumin is fused to the C-terminus of the antibody construct. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Optimized cross-species specific bispecific single chain antibody contructs

Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3

Antibody constructs for EGFRVIII and CD3

Growing community of inventors

Munich, Germany

Ines Herrmann